Clinical Trials Logo

Clinical Trial Summary

Hypertension is a leading risk factor for morbidity and mortality worldwide. The brain is a major target of the damaging effects of hypertension. Hypertension has been recognized as the leading cause of dementia as well as the most important risk factor for stroke and vascular cognitive impairment. Although glucose is the principal cerebral energy source, impact of hypertensive treatment on cerebral glucose metabolism is poorly understood.

Clinical Trial Description


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

  • Efficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension
  • Inflammation

NCT number NCT02996916
Study type Interventional
Source Kurume University
Contact Nobuhiro Tahara, MD, PhD
Phone +81-942-31-7580
Email [email protected]
Status Recruiting
Phase Phase 4
Start date December 2015
Completion date December 2020